CD19 and acute lymphoblastic leukemia: The use of SB transposition for CAR‐NK cell generation is a promising approach for non‐viral and efficient CD19‐CAR‐NK cell manufacturing, and a high anti‐tumour response has been demonstrated against B‐ALL cell lines, patient‐derived samples, and in vivo xenograft models [20, 22].